<DOC>
	<DOCNO>NCT00895934</DOCNO>
	<brief_summary>The purpose study test safety vorinostat ( Zolinza ) azacitidine ( Vidaza ) combine gemtuzumab ozogamicin ( GO ) different dose level . These drug increase effect GO leukemia cell test tube , n't know yet whether also increase anti-leukemia effect GO people .</brief_summary>
	<brief_title>Vorinostat , Azacitidine , Gemtuzumab Ozogamicin Older Patients With Relapsed Refractory AML</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine vorinostat dose favorable efficacy toxicity combine azacitidine GO . SECONDARY OBJECTIVES : I . Describe complete response ( CR ) / CR inadequate recovery ( CRi ) rate total 6 cycle therapy . II . Describe disease-free survival patient achieve CR/CRi . III . Determine whether acute myeloid leukemia ( AML ) characteristic associated preclinical GO efficacy predict clinical benefit , ass whether differentiation-inducing agent modulate characteristic lower apoptotic threshold calicheamicin-gamma1-induced cytotoxicity ( vitro correlative mechanistic study ) . OUTLINE : This phase I , dose-escalation study vorinostat follow phase II study . Patients receive vorinostat orally ( PO ) day 1-9 , azacitidine subcutaneously ( SC ) intravenously ( IV ) 10-40 minute day 1-7 , gemtuzumab ozogamicin IV 2 hour day 4 8 . Treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Prior morphological diagnosis acute myeloid leukemia ( AML ) acute promyelocytic leukemia ( APL ) accord 2001 WHO criteria ; patient biphenotypic AML eligible Need first salvage chemotherapy persistent relapse disease , define standard criterion , least one course conventional chemotherapy A bone marrow biopsy require obtained aspirate dilute , hypocellular , aspirable ; outside marrow exam perform within stipulated time period acceptable slide review study institution Flow cytometric analysis marrow aspirate per institutional practice guideline Duration first complete remission ( CR1 ) &lt; 12 month ( primary resistant disease ) Patients prior autologous allogeneic hematopoietic cell transplantation ( HCT ) relapse occur 612 month posttransplant ECOG/WHO/Zubrod performance status 03 within 14 day prior registration Off active therapy AML except hydroxyurea least 14 day prior study registration , resolution grade 3 4 nonhematological toxicity Willingness discontinue take medication know cause risk Torsades de Pointes Bilirubin = &lt; 1.5 x Institutional Upper Limit Normal ( IULN ) unless elevation due hepatic infiltration AML , Gilbert 's syndrome , hemolysis ( within 7 day prior registration ) SGOT ( AST ) SGPT ( ALT ) = &lt; 1.5 x IULN unless elevation due hepatic infiltration AML ( within 7 day prior registration ) Serum creatinine = &lt; 1.5 x IULN ( within 7 day prior registration ) No clinical radiographical evidence heart failure white blood cell ( WBC ) &lt; 25,000/uL within 3 day prior registration Patients symptoms/signs hyperleukocytosis WBC &gt; 100,000/uL treated leukapheresis prior enrollment Collection bone marrow peripheral blood specimen correlative study prior study treatment highly recommend ; peripheral blood acceptable peripheral blast count &gt; 5,000/uL &gt; 50 % total WBC Must agree use adequate contraception prior study Can understand sign write informed consent document ; legally authorize representative provide consent patient unable Remission second later relapse Diagnosis another malignancy , unless diagnose least 2 year earlier diseasefree least 6 month completion curative intent therapy except : Treated nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , definitive treatment complete Organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value hormonal therapy initiate radical prostatectomy perform Refractory/relapsing blast crisis chronic myeloid leukemia ( CML ) Prior antiAML treatment GO , histone deacetylase ( HDAC ) inhibitor ( include use valproic acid control seizure activity purpose ) , demethylating agent Known hypersensitivity GO , vorinostat , azacitidine , mannitol Possible central nervous system ( CNS ) involvement leukemia unless lumbar puncture confirm leukemic blast cerebralspinal fluid ( CSF ) HIVpositive patient cluster differentiation ( CD ) 4 count &lt; 200 cells/uL AIDSrelated complication Pregnancy ; breastfeed discontinue mother treated vorinostat , azacitidine , GO Uncontrolled systemic infection , despite appropriate antibiotic treatment ) Receipt investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>